Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company’s shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com
Company’s Keywords:
clinisenz, onzurf, tetragraph
44
medical devices
69000
Outlook, Microsoft Office 365, Hubspot, Apache, Typekit, Google Analytics, WordPress.org, Cision, Mobile Friendly, Google Maps (Non Paid Users), Multilingual, Nginx, Google Maps, Google Tag Manager
1999